Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole for Prevention of LDA-Associated Ulcers
NCT01069939Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2010
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in gastric ulcer and duodenal ulcer comparing Esomeprazole 20mg with Placebo (2 arms). Primary endpoint: Time From Randomization to Occurrence of Gastric and/or Duodenal Ulcers at 48 weeks. Started Feb 2010; status: completed.
02
Drugs
esomeprazole
03
Conditions
gastric ulcerduodenal ulcer
Beyond the preview
Go deeper on NCT01069939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01069939.